Using ex vivo drug sensitivity profiles, researchers have identified a novel chemotherapy regimen effective in treating relapsed, multidrug-resistant ovarian cancer. Two separate trials in which gemcitabine and cisplatin were administered sequentially on the same days are reported in the January issue of Gynecologic Oncology.
Dr. Robert A. Nagourney, of Rational Therapeutics Inc. in Long Beach, California, and associates have developed an assay that measures drug-induced tumor cell apoptosis rather than cell proliferation-based endpoints. The assay revealed high degrees of cytotoxic activity and synergy for the gemcitabine/cisplatin combination in ovarian cancer specimens.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!